DALLAS, May 1, 2025 — Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced that Dr. Subrata Batabyal, Director of Nonclinical Development, has received 2025 Carl Camras Translational Research Award from the ARVO Foundation for his pioneering work in optogenetic vision restoration.

The award, which comes with a $12,000 prize, recognizes early-career investigators engaged in translational research. Dr. Batabyal significantly contributed to the translation of multi-characteristic opsin (MCO-010), an innovative gene therapy that uses light-sensitive proteins to restore vision in patients with inherited retinal diseases. The therapy has successfully progressed from laboratory studies to clinical trials, demonstrating promising results in treating patients with retinitis pigmentosa and other inherited retinal disorders. Dr. Batabyal will receive the award during The Association for Research and Vision in Ophthalmology (ARVO) 2025 annual meeting, to be held in Salt Lake City from May 4-8.

The ARVO Foundation Awards Reception details are as follows:

Date: Sunday, May 4, 2025
Time: 11:45 am – 1:00 pm MT
Location: Calvin L. Rampton Salt Palace Convention Center, Room 155EF

“Dr. Batabyal continues to lead groundbreaking research initiatives in vision restoration at Nanoscope,” said Dr. Samarendra Mohanty, Co-Founder and President of Nanoscope. “He is representative of the outstanding team we have assembled, which is developing next-generation vision restoration treatments that could benefit potentially millions of patients worldwide who currently have limited treatment options.”

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure currently exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate in 2025 a BLA submission for MCO-010 to treat RP. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical programs include an IND-ready, non-viral, laser-delivered MCO-020 asset for GA, as well as an AAV asset for Leber Congenital Amaurosis, in IND-enabling studies.

Investor Contact:
Argot Partners
212-600-1902
[email protected]

SOURCE Nanoscope Therapeutics